Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 91 to 100 of 1329 total matches.
Sildenafil: An Oral Drug for Impotence
The Medical Letter on Drugs and Therapeutics • May 08, 1998 (Issue 1026)
). The drug is metabolized in the liver to an active metabolite, primarily by CYP3A4. It is excreted largely ...
Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).
Interferon Plus Ribavirin for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Jun 04, 1999 (Issue 1054)
to normalization of serum aminotransferase activity in 40% to 50% of patients with
chronic hepatitis C and loss ...
Rebetron, a combination of injected recombinant interferon alfa-2b with oral ribavirin has been approved by the FDA for treatment of chronic hepatitis C virus infection.
Bupivacaine Liposome Injection (Exparel) for Postsurgical Pain
The Medical Letter on Drugs and Therapeutics • Apr 02, 2012 (Issue 1387)
Injection
(Exparel) for Postsurgical Pain
The first study compared infiltration of 120 mg of the
active ...
The FDA has approved a new formulation (Exparel –
Pacira) of the local anesthetic bupivacaine (Marcaine,
and others) for use in the management of postsurgical
pain in adults.
Teprotumumab (Tepezza) for Thyroid Eye Disease
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
.
Teprotumumab is a fully human IgG1 monoclonal
antibody that binds to IGF-1R, blocking its activation ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like
growth factor-1 receptor (IGF-1R) inhibitor, has
been approved by the FDA for IV treatment of thyroid
eye disease. It is the first drug to be approved in the US
for this indication.
Nitazoxanide (Alinia) -- a New Anti-protozoal Agent
The Medical Letter on Drugs and Therapeutics • Apr 14, 2003 (Issue 1154)
of choice (The Medical Letter
Handbook of Antimicrobial Therapy, 16th edition, page 127).
ACTIVITY ...
Nitazoxanide (Alinia - Romark Labs), a new antiparasitic drug, has been approved by the FDA in a liquid formulation for treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia in children 1 to 11 years old. It is the first drug approved for treatment of cryptosporidiosis and the first to become available as a liquid for treatment of giardiasis. The FDA is reviewing a tablet formulation of nitazoxanide for use in adults.
Lubiprostone (Amitiza) for Chronic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006 (Issue 1236)
activator, for
treatment of chronic idiopathic constipation in adults.
The only other prescription drug ...
The FDA has approved lubiprostone (Amitiza - Sucampo/Takeda), a chloride channel activator, for treatment of chronic idiopathic constipation in adults. The only other prescription drug approved by the FDA for this indication (in 2004 for adults <= 65 years old) is tegaserod (Zelnorm), a partial agonist of serotonin that is also approved for constipation-predominant irritable bowel syndrome in women. Of course, numerous over-the-counter products are available for treatment of constipation.
Rifamycin (Aemcolo) for Treatment of Travelers' Diarrhea
The Medical Letter on Drugs and Therapeutics • Mar 11, 2019 (Issue 1567)
and fluoroquinolones are active against
most invasive and noninvasive bacterial pathogens
that cause TD ...
The FDA has approved rifamycin (Aemcolo – Cosmo/
Aries), a minimally absorbed oral antibiotic, for
treatment of adults with travelers' diarrhea (TD)
caused by noninvasive strains of Escherichia coli. It
is not recommended for treatment of diarrhea that is
complicated by fever and/or bloody stools. Topical
and injectable formulations of rifamycin have been
used in Europe for other indications for many years.
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
has antiandrogenic properties that may
improve acne, but it also has antimineralocorticoid
activity that can cause ...
The FDA has approved a combination oral
contraceptive containing the estrogen estetrol and the
progestin drospirenone (Nextstellis – Mithra/Mayne).
Estetrol is the first new estrogen to become available
in the US in 50 years. Drospirenone is available alone
(Slynd) and in combinations with the estrogen ethinyl
estradiol for prevention of pregnancy.
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
bacterial sinusitis in adults and children5,6; addition
of clavulanate to amoxicillin improves its activity ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
Metrodin and Other Drugs That Induce Ovulation
The Medical Letter on Drugs and Therapeutics • Sep 23, 1988 (Issue 775)
is the drug of choice for anovulatory or oligoovulatory women with endogenous estrogen activity and an intact ...
Urofollitropin (Metrodin - Serono), a human gonadotropin, is the latest drug to be approved by the US Food and Drug Administration (FDA) for induction of ovulation in various clinical situations, including in vitro fertilization (IVF).